Brian O Mahony/X
Jul 21, 2025, 13:10
What’s Slowing Down Gene Therapy Uptake in Hemophilia? Brian O’Mahony Explains the Real-World Barriers
Brian O’Mahony, CEO of Irish Haemophilia Society,former President of WFH and EHC, highlights several key challenges that are currently limiting the widespread adoption of gene therapy in hemophilia in his recently shared post on X:
“Uncertainty about outcomes and side effects,
Complex reimbursement systems,
Availability of other excellent therapies,
Lack of center preparedness and resources.”
Despite the promise of a functional cure, real-world barriers continue to delay broader implementation.
Want to understand the future of gene therapy and how to overcome systemic obstacles?
Find the latest updates and expert commentary — only on Hemostasis Today, your trusted source for frontline academic insights in hematology and hemostasis.
-
Apr 22, 2026, 07:56Shruti Kharat: Closing the Gap in Early Detection of Factor VIII Inhibitors
-
Apr 22, 2026, 07:46Gregory Piazza: Ushering in a New Era in PE Therapy and Improved Clinical Outcomes for Our Patients
-
Apr 22, 2026, 07:40Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
-
Apr 22, 2026, 07:36Selma Turkovic: Blood Transfusion Education and Discussion Group Webinar 61
-
Apr 22, 2026, 07:34Aikati Anastasiou: Advancing Stroke Imaging Insights from the DISTAL Trial
-
Apr 22, 2026, 07:26Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?
-
Apr 22, 2026, 07:19Sarah Richardson: Bringing Insights from HFA Symposium Back to Real Life
-
Apr 22, 2026, 07:17Karuna Kumar: Interesting Trial from Gambia on Treating Iron Deficiency in Children
-
Apr 22, 2026, 07:12Mary Catherine Moffett: Celebrating 32 Years of Patient-Centered Advocacy with the Hemophilia Federation of America